Fragile X Syndrome and Targeted Treatments
Clicks: 179
ID: 114407
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
1.8
/100
6 views
6 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Many targeted treatment studies have been carried out in individuals with Fragile X Syndrome (FXS) guided by animal studies from the Fragile X Mental Retardation 1 ( FMR1) knock out (KO) mice and the fragile X Drosophila studies. Here we review the many medications that have been studied in patients with FXS and some of these medications are available for clinical use by wise clinicians. Other medications are not currently available by prescription because they are not approved by the FDA. No medication has received specific approval for treatment of FXS, although some have shown benefit from clinical studies. There is much to be done in the treatment of those with FXS and this report describes those pharmacological treatments that target the neurobiological mechanisms that are dysregulated by the lack of the Fragile X Protein (FMRP) in those with FXS.
| Reference Key |
tassanakijpanich2020journalfragile
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nattaporn Tassanakijpanich;Ana María Cabal-Herrera;Maria Jimena Salcedo-Arellano;Randi Jenssen Hagerman; |
| Journal | journal of biomedicine and translational research |
| Year | 2020 |
| DOI |
7321
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.